Merck KGaA (MKGAF)
| Market Cap | 61.48B |
| Revenue (ttm) | 21.90B |
| Net Income (ttm) | 2.88B |
| Shares Out | n/a |
| EPS (ttm) | 6.61 |
| PE Ratio | 21.38 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35 |
| Average Volume | 1,471 |
| Open | 138.00 |
| Previous Close | 141.75 |
| Day's Range | 138.00 - 138.00 |
| 52-Week Range | 135.00 - 200.56 |
| Beta | 0.74 |
| RSI | 43.17 |
| Earnings Date | Mar 6, 2025 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing a... [Read more]
Full Company ProfileFinancial Performance
In 2024, Merck KGaA's revenue was 21.16 billion, an increase of 0.78% compared to the previous year's 20.99 billion. Earnings were 2.78 billion, a decrease of -1.66%.
Financial numbers in EUR Financial StatementsNews
Merck KGaA: Still A Bit Too Expensive
Merck KGaA's stock remains a 'hold' due to its high valuation, trading at an earnings multiple of around 20 and a 4.5% free cash flow yield. Read why MKGAF is a hold.
Merck KGaA (MKGAF) Q4 2024 Earnings Call Highlights: Strong Organic Growth and Strategic ...
Merck KGaA (MKGAF) Q4 2024 Earnings Call Highlights: Strong Organic Growth and Strategic Investments Propel Performance
Resilience is part of our DNA, says Merck KGaA CEO
Belén Garijo, CEO of Merck KGaA, said the German pharmaceutical company has increased its readiness to deal with the ongoing geopolitical uncertainty, and is confident it will continue delivering prof...
Merck KGaA (MKGAF) Q4 2024 Earnings Call Transcript
Resilience is part of our DNA, says Merck KGaA CEO
Beln Garijo, CEO of Merck KGaA, said the German pharmaceutical company has increased its readiness to deal with the ongoing geopolitical uncertainty, and is confident it will continue delivering profi...
Merck KGaA Sees Profit Growth in 2025 as Recovery Takes Hold
Merck KGaA forecast rising profit this year as its life science business continues to recover and the boom in AI lifts demand at its semiconductor division.
Merck KGaA Non-GAAP EPS of €8.63, revenue of €21.16B; initiates FY25 outlook
Merck KGaA press release (MKGAF): FY Non-GAAP EPS of €8.63. Revenue of €21.16B (+0.8% Y/Y) (organically: +2.0%). EBITDA pre rose to € 6.1 billion (organically: +6.9%). Stable dividend
Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results
Merck KGaA sees forex-adjusted earnings growth of up to 8% this year
Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor chemicals and for lab equipment in biotech drug production.
Merck KGaA to replace two executives with company veterans
Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new leadership from June but it added that its strategy remains unchanged.
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics
Merck KGaA is in advanced talks to ... Full story available on Benzinga.com
Crude Oil Rises Sharply; Manhattan Associates Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping more than 150 points on Monday. The Dow traded up 0.40% to 44,482.54 while the NASDAQ gained 1.16% to 19,750.22. T...
Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining around 200 points on Monday. Shares of Rockwell Automation, Inc. (NYSE: ROK) rose sharply during Monday's session after the company reported...
SpringWorks Therapeutics jumps on report of Merck KGaA takeover talks
Exclusive: Germany's Merck KGaA in talks to buy US cancer biotech firm Springworks, sources say
Merck KGaA , the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics , according to people familiar with the matter...
Merck KGaA says high asset prices call for prudent M&A approach
The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.
MilliporeSigma Partners with Opentrons Labworks, Inc., Supporting Lab of the Future
Custom robotic workstation automates company’s broad portfolio of biology assays for academia, biotech, and pharma Meets growing need for autonomous tools that boost throughput and reproducibility Pro...
Merck KGaA, Darmstadt, Germany Announces Launch of Caregiver Leave Benefit, Strengthening Inclusive Family-Friendly Offerings
Caregiver Leave Benefit to offer financially protected 10-day minimum leave to employees globally Primarily aimed to support the care of critically and terminally ill immediate family members Program ...
EU ship can be 'turned around,' Merck KGaA CEO says
Beln Garijo, CEO of Merck KGaA, weighs in on Europe's competitiveness and the pharma giant's preparations for the impact of potential U.S. trade tariffs.
Mirror Biologics Enters Clinical Collaboration with Merck KGaA, Darmstadt, Germany in Metastatic Colorectal Cancer
TAMPA, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mirror Biologics, Inc., specializing in development and manufacturing of immunotherapy products where the active ingredient is living, non-genetically al...
MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
Reinforces company’s commitment to differentiated solutions that enable faster and more effective drug development HUB’s organoid offering complements company’s cell culture portfolio of media, reagen...
MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio
HUB internationally recognized pioneer in organoid development Acquisition expands MilliporeSigma’s 2D and 3D cell culture portfolio Organoids part of fastest growing cell culture segment; hold potent...
Merck KGaA (MKGAF) Q3 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor RelationsBelen...
Merck KGaA 2024 Q3 - Results - Earnings Call Presentation
Merck KGaA continues focus on strengthening pipeline with external innovation, says CFO on drug trials
Merck KGaA CFO Helene von Roeder discusses the group's third-quarter earnings and its progress with drug trials.